Archer Investment Corporation’s Neurocrine Biosciences NBIX Stock Holding History

Archer Investment Corporation’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.69K	Hold	10	–	–	﹤0.01%	1083
2026 Q1	$1.32K	Hold	10	–	–	﹤0.01%	1090
2025 Q4	$1.42K	Hold	10	–	–	﹤0.01%	1023
2025 Q3	$1.4K	Hold	10	–	–	﹤0.01%	1035
2025 Q2	$1.26K	Hold	10	–	–	﹤0.01%	1018
2025 Q1	$1.11K	Sell	10 -730	-99%	-$92.5K	﹤0.01%	990
2024 Q4	$101K	Hold	740	–	–	0.03%	335
2024 Q3	$85.3K	Buy	740 +200	+37%	+$27.4K	0.02%	365
2024 Q2	$74.3K	Hold	540	–	–	0.02%	372
2024 Q1	$74.5K	Hold	540	–	–	0.02%	365
2023 Q4	$71.2K	Hold	540	–	–	0.02%	347
2023 Q3	$60.8K	Buy	540 +10	+2%	+$1.05K	0.02%	357
2023 Q2	$50K	Hold	530	–	–	0.02%	384
2023 Q1	$51.4K	Buy	+530	New	+$55.2K	0.02%	383

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Archer Investment Corporation's NBIX Position: Q2 2026 in Review

Archer Investment Corporation held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 10 shares worth $1.69K. The position accounts for ﹤0.01% of the portfolio, ranked #1083.

Archer Investment Corporation first reported a position in NBIX in Q1 2023 and has held it in 14 quarters since. The position peaked at $101K in Q4 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Archer Investment Corporation held 10 shares of Neurocrine Biosciences worth $1.69K as of Q2 2026.
Archer Investment Corporation left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Archer Investment Corporation's portfolio in Q2 2026, its #1083 holding.
Archer Investment Corporation first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 14 quarters since.
Archer Investment Corporation's Neurocrine Biosciences position peaked at $101K in Q4 2024.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Archer Investment Corporation's 13F filing for Q2 2026, filed 3 Aug 2026.